Figure 3From: Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapyPredicted daily utility by pollen count, stratified by treatment arm (GRAZAX®, red: placebo, green; dotted lines represent 95% CIs) .Back to article page